CPRX Catalyst Pharmaceuticals Inc

$20.25

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/19/2025

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.

Website: https://catalystpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1369568
Address
355 ALHAMBRA CIRCLE, SUITE 1250, CORAL GABLES, FL, US
Valuation
Market Cap
$2.75B
P/E Ratio
17.19
PEG Ratio
0.00
Price to Book
3.77
Performance
EPS
$1.31
Dividend Yield
—
Profit Margin
33.30%
ROE
29.40%
Technicals
50D MA
$22.63
200D MA
$20.96
52W High
$26.16
52W Low
$14.47
Fundamentals
Shares Outstanding
122M
Target Price
$33.88
Beta
0.79

CPRX EPS Estimates vs Actual

● Estimated
● Actual

CPRX News & Sentiment

Aug 19, 2025 • GlobeNewswire BULLISH
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® ( Vamorolone ) in five GCC ( Gulf Cooperation Council ) Countries
Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® ( vamorolone ) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment ...
Aug 15, 2025 • Zacks Commentary BULLISH
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 15, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Santhera extends Highbridge convertible bond to 30th September 2025
Ad hoc announcement pursuant to Art. ...
Aug 13, 2025 • Zacks Commentary BULLISH
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Aug 13, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® ( Vamorolone ) in Türkiye
Pratteln, Switzerland, 13 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. ( GEN ) for the distribution and promotion of AGAMREE® ( vamorolone ) in Türkiye for the treatment of Duchenne ...
Aug 07, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Sentiment Snapshot

Average Sentiment Score:

0.398
50 articles with scored sentiment

Overall Sentiment:

Bullish

CPRX Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Post market)
0.38 Surprise
  • Reported EPS: $0.70
  • Estimate: $0.32
  • Whisper: —
  • Surprise %: 118.8%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.35
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: 16.7%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $0.33
  • Estimate: $0.26
  • Whisper: —
  • Surprise %: 26.9%
May 08, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.17
  • Whisper: —
  • Surprise %: 11.8%
Feb 28, 2024
Dec 31, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.31
  • Estimate: $0.27
  • Whisper: —
  • Surprise %: 14.8%
Nov 08, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.29
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: -3.6%
Aug 09, 2023
Jun 30, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $0.53
  • Estimate: $0.42
  • Whisper: —
  • Surprise %: 26.2%
May 10, 2023
Mar 31, 2023 (Post market)
-0.06 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.32
  • Whisper: —
  • Surprise %: -18.8%
Mar 15, 2023
Dec 31, 2022 (Post market)
0.01 Surprise
  • Reported EPS: $0.22
  • Estimate: $0.21
  • Whisper: —
  • Surprise %: 4.8%

Financials